KLRA peer analysis
Kailera Therapeutics (KLRA) against its competitors: price, today's move, 1-year return and market value side by side.
KLRA and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALT Altimmune | $2.14 | 2.88% | -45.69% | $416.27M |
| BIOA BioAge Labs | $5.68 | 6.37% | -28.51% | $245.38M |
| BMEA Biomea Fusion | $0.60 | 5.63% | -56.40% | $41.08M |
| GUTS Fractyl Health | $0.91 | -2.67% | -92.89% | $12.33M |
| MBX MBX Biosciences | $54.02 | 5.20% | 107.56% | – |
| MTVA MetaVia | $1.43 | 31.19% | -84.71% | $9.42M |
| NAMS NewAmsterdam Pharma | $18.96 | 0.34% | -48.99% | $2.27B |
| ORMP Oramed | $3.86 | -0.77% | 75.45% | $160.57M |
| VKTX Viking Therapeutics | $29.00 | 8.05% | -27.98% | $3.42B |
| VTVT vTv Therapeutics | $21.03 | -3.27% | -17.43% | $83.15M |
| KLRA Kailera Therapeutics | $14.89 | 14.80% | – | $1.68B |
- KLRA's peers: ALT (Altimmune), BIOA (BioAge Labs), BMEA (Biomea Fusion), GUTS (Fractyl Health), MBX (MBX Biosciences), MTVA (MetaVia), NAMS (NewAmsterdam Pharma), ORMP (Oramed).
Updated 2026-11-10 04:46 UTC